The increased focus on reducing frank psychosis in the clinical high risk for psychosis population may have inadvertently diverted attention from the identification of schizotypy and mapping its clinical trajectories, and may have reduced interest in evaluating specific therapies for this population. Further long-term longitudinal studies, ideally from childhood and adolescence, are required to map possible stages of schizotypal disorder and to test treatments according to stage of disorder evolution.